Citation Impact
Citing Papers
Prediction of Postoperative Pulmonary Complications in a Population-based Surgical Cohort
2010 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2007 Standout
Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters
1990
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Primary liver cancer: Worldwide incidence and trends
2004 Standout
Doxorubicin pathways
2010 Standout
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
2004 Standout
Disorders of Ciliary Motility
2001
Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown
2003
Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications
2003 Standout
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Targeted delivery of low dose doxorubicin hydrochloride administered via magnetic albumin microspheres in rats
1990
Global Initiative for Chronic Obstructive Lung Disease
2002 Standout
TFOS DEWS II Diagnostic Methodology report
2017 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis
1996 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Chemotherapy for advanced gastric cancer
2010
Chemotherapy for advanced gastric cancer
2005
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Regulation of mucociliary clearance in health and disease
1999
Toxicity profile of dexrazoxane (zinecardR, icrf-187, adr-529, nsc-169780), a modulator of doxorubicin cardiotoxicity
1991
Clinical Pharmacokinetics of Doxorubicin
1988
Physiological pharmacokinetie model of adriamycin delivered via magnetic albumin microspheres in the rat
1989
Oral chemotherapy: rationale and future directions.
1998
5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma
1994
Catalytic inhibitors of DNA topoisomerase II
1998
Quantitative Deposition of Aerosolized Gentamicin in Cystic Fibrosis
1987
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
2008 Standout
Doxorubicin clearance in the obese.
1988
Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells
1998
TFOS DEWS II Management and Therapy Report
2017 Standout
Gastric cancer
2020 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Short‐term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: A cross‐over randomized study
1995
Repeatability of airway deposition and tracheobronchial clearance rate over three days in chronic bronchitis
1995
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Clinical Pharmacology of 5-Fluorouracil
1989 Standout
Effects of Punctal Occlusion on Clinical Signs and Symptoms and on Tear Cytokine Levels in Patients with Dry Eye
2016
Antibody-targeted polymer-bound drugs
1995
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Are Incentive Spirometry, Intermittent Positive Pressure Breathing, and Deep Breathing Exercises Effective in the Prevention of Postoperative Pulmonary Complications After Upper Abdominal Surgery? A Systematic Overview and Meta-analysis
1994
The dawning era of polymer therapeutics
2003 Standout
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Asthma
2000 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2001 Standout
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
2003 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Patterns of metastasis and natural courses of breast carcinoma
1985
Postoperative atelectasis and pneumonia
1995
Antineoplastic Drugs
1978
Oral theophylline for chronic obstructive pulmonary disease
2002
Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
1983
Long-lasting response to cis-platinum in recurrent malignant thymoma
1982
Pulmonary rehabilitation for chronic obstructive pulmonary disease
2015 Standout
Cytokine changes in tears and relationship to contact lens discomfort.
2015
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2′-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea. A phase II-III study of the eastern cooperative oncology group (EST 4273)
1978
Drug effects on the liver
1983
Prognostic effect of weight loss prior tochemotherapy in cancer patients
1980 Standout
Tracheobronchial mucociliary clearance in asthma: impairment during remission.
1985
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion
1978
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
2001 StandoutNobel
Chemotherapy for advanced gastric cancer
2017 Standout
Fluorouracil Therapy in Patients With Carcinoma of the Large Bowel
1978
Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy
1989
The influence of cimetidine on the pharmacokinetics of 5‐fluorouracil.
1984
Modulation of 5-fluorouracil toxicity by allopurinol in man
1981
Managing Cough as a Defense Mechanism and as a Symptom
1998
Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug
1986
PULMONARY REHABILITATION IN THE ELDERLY PATIENT
1993
Cancer, Clinical Pharmacology, and Aging
1987
The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003
2003 Standout
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
1980
Interpretation of "24 Hour Lung Retention" in Studies of Mucociliary Clearance
1988
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee
2004 Standout
Clinical Practice Guideline (Update): Adult Sinusitis
2015 Standout
An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation
1980 StandoutNobel
Clinical practice guideline: Adult sinusitis
2007 Standout
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
2001
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
The clinical course of bone metastases from breast cancer
1987 Standout
Lung Infections Associated with Cystic Fibrosis
2002 Standout
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs
1982
The human tumor cloning assay in cancer drug development
1983 StandoutNobel
Plasma levels of 5‐fluorouracil after oral and intravenous administration in cancer patients.
1979
AETIOPATHOGENESIS OF HEPATOCELLULAR CARCINOMA
1996
Cisplatin
1984 Standout
Pharmacologic studies of anticancer drugs with the human tumor stem cell assay
1981
Particle deposition and clearance in the bronchial tree
1981
Works of Bateman being referenced
Tear cytokine response to multipurpose solutions for contact lenses
2013
Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.
1981
Treatment of advanced gastric carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery.
1980
The effect of oral aminophylline on lung mucociliary clearance in man.
1981
Deposition and clearance of inhaled particles.
1980
Chest physiotherapy: a review.
1982
Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).
1975
Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
1978
Concomitant razoxane and doxorubicin treatment on a weekly schedule.
1984
The importance of aerosol penetration for lung mucociliary clearance studies.
1981
Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model.
1978
Investigation of mechanism and type of jaundice produced by large doses of parenterally administered aureomycin.
1953
5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: comparison of oral and intravenous routes.
1976
Clinical trial of weekly doses of vinblastine (NSC-49842) combined with vincristine (NSC-67574) in malignant lymphomas and other neoplasms.
1974
Frequency and treatment of primary hepatocellular carcinoma in Los Angeles.
1981